8-K: Boston Scientific EVP Mirviss to Retire, Transition to Advisor
Executive Retirement Announcement
Boston Scientific Corporation announced the planned retirement of Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions, effective December 1, 2025.
Summary
- Jeffrey B. Mirviss will retire from his role as Executive Vice President and President, Peripheral Interventions, effective December 1, 2025.
- Mr. Mirviss will transition to a senior advisor role from December 1, 2025, through February 27, 2026, which is designated as his Retirement Date.
- During his tenure as a senior advisor, Mr. Mirviss will receive his current annual base salary of $705,000, prorated through the Retirement Date.
- The Company expects to enter into a Retirement Agreement with Mr. Mirviss, consistent with the terms of its Executive Retirement Plan, 2025 Annual Bonus Plan, Long-Term Incentive Program, and equity awards.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While an executive departure can be seen as a negative, the planned nature of the retirement and the inclusion of a transition period as a senior advisor mitigate immediate concerns about leadership disruption.
Positives
- The planned transition period, with Mr. Mirviss serving as a senior advisor until February 27, 2026, allows for an orderly handover and continuity.
- The retirement agreement aligns with existing company plans and equity awards, indicating a structured and pre-defined executive departure process.
Negatives
- The departure of an Executive Vice President and President of a key division (Peripheral Interventions) represents a loss of experienced leadership.
Future Outlook
The company expects to finalize a Retirement Agreement with Mr. Mirviss, consistent with existing executive compensation and incentive plans.
Industry Context
Executive retirements are a normal course of business for large, established medical technology companies like Boston Scientific. The structured transition period is a common practice to ensure leadership continuity in key divisions.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Executive Vice President and President, Peripheral Interventions | Jeffrey B. Mirviss | To be announced (implied) | 2025-12-01 | Retirement |
Stakeholder Impact
- Shareholders may monitor the appointment of a successor to ensure continued strong leadership in the Peripheral Interventions division.
- Employees within the Peripheral Interventions division may experience leadership changes and potential strategic shifts under new management.
Next Steps
- Boston Scientific Corporation expects to enter into a Retirement Agreement with Mr. Mirviss effective as of his Retirement Date.
Key Dates
| Date | Description |
|---|---|
| 2025-08-29 | Date Jeffrey B. Mirviss informed Boston Scientific Corporation of his decision to retire. |
| 2025-12-01 | Effective date of Mr. Mirviss's retirement from his role as Executive Vice President and President, Peripheral Interventions, and commencement of his senior advisor role. |
| 2026-02-27 | The Retirement Date, marking the end of Mr. Mirviss's senior advisor role. |
| 2025-09-04 | Date the Form 8-K report was signed. |
Keywords
Boston Scientific, BSX, Executive Retirement, Management Change, Peripheral Interventions, Jeffrey B. Mirviss, Senior Advisor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.